Collegium Pharmaceutical, Inc. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
Collegium Pharmaceutical, Inc. (COLL) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 131.26 thousand shares for the 12-month period ending 2021-12-31, per its 10-K filed 2024-02-22.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2024-02-22
- Collegium Pharmaceutical, Inc. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2021 was 131.26K shares, a 928.74% increase from fiscal 2020.
- Collegium Pharmaceutical, Inc. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2020 was 12.76K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month |
|---|---|
| 2021-12-31 | 131.26K shares 10-K · filed 2024-02-22 |
| 2020-12-31 | 12.76K shares 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |